We explored the influence of exposure to maternal diabetes in utero on β cell decline measured by fasting C-peptide (FCP) among 1079 youth < 20 years with diabetes, including 941 with type 1 and 138 with type 2 diabetes. Youths exposed to maternal diabetes had FCP levels that were 17% lower among youth with type 2 diabetes [95% confidence interval (CI): -34%, + 6%] and 15% higher among youth with type 1 diabetes (95%CI: -14%, + 55%) than their unexposed counterparts, although differences were not statistically significant (p = 0.13 and p = 0.35, respectively). Exposure to maternal diabetes was not associated with FCP decline in youth with type 2 (p = 0.16) or type 1 diabetes (p = 0.90); nor was the effect of in utero exposure on FCP modified by diabetes type. Findings suggest that exposure to maternal diabetes in utero may not be an important determinant of short-term β -cell function decline in youth with type 1 or type 2 diabetes.
Introduction
A relationship between exposure to maternal diabetes in utero and increased risk of type 2 diabetes in the offspring has been reported among diverse populations in the USA (1 -3) and Europe (4, 5) . Within the Pima Indian population, siblings born after their mother had been diagnosed with type 2 or gestational diabetes mellitus (GDM) had a three-fold higher risk of developing type 2 diabetes than siblings born before the diagnosis (2) . Results from the SEARCH Case-Control Study indicate that non-Hispanic white, Hispanic and African American youths with type 2 diabetes were 5.7 times more likely to have been exposed to maternal diabetes in utero (mostly GDM) than controls [95% confidence interval (CI): 2.4 -13.4, p < 0.0001] (1) . A study by Clausen et al. (4) of Caucasian young adults in Denmark found that more than 20% of offspring born to mothers with GDM and 10% of offspring born to mothers with type 1 diabetes had type 2 or pre-diabetes by the age of 22, suggesting a predisposition that is independent of maternal diabetes type. Moreover, the SEARCH study has reported that, among youth with type 2 diabetes, exposure to maternal diabetes in utero was associated with a 1.68 year younger age at diagnosis (6) (p = 0.018), while there was no significant association with paternal diabetes status (p = 0.853), suggesting an independent effect of the intrauterine exposure to hyperglycemia that extends beyond shared genetic and environmental factors. However, a relationship between age at diagnosis and in utero exposure to maternal diabetes was not detected for youth with type 1 diabetes.
Animal studies have demonstrated hyperplasia and hyperactivity of pancreatic β cells in offspring of diabetic pregnancies (7 -9) . However, there are no epidemiologic data in human populations exploring whether exposure to maternal diabetes in utero influences β -cell function at diagnosis and the subsequent rate of β -cell function decline in children with diabetes. C-peptide is an extensively studied biochemical marker of β -cell function/ insulin secretion. Unlike insulin, it does not undergo hepatic first pass metabolism, has a longer half-life, and is recognized as a more stable and accurate marker of endogenous insulin secretion than serum insulin levels (10, 11) . We used data from the SEARCH for Diabetes in Youth Study to test the hypothesis that exposure to maternal diabetes in utero will be associated with a faster rate of decline in fasting C-peptide (FCP) levels after diabetes diagnosis among youth with type 2, but not in those with type 1 diabetes.
Methods
Data for these analyses come from the SEARCH for Diabetes in Youth prospective cohort study. A detailed description of the SEARCH study methods has been published elsewhere (12) . Briefl y, SEARCH has been conducting population-based ascertainment of youth < 20 years old with newly diagnosed (incident) diabetes starting in 2002 and continuing through the present. SEARCH recruited participants from four geographically defi ned populations in Ohio, Colorado, South Carolina and Washington, as well as from Indian Health Service benefi ciaries of several American Indian populations, and enrollees in several managed health care plans in California and Hawaii. Participants are invited to participate in a baseline research visit and follow-up exams at approximately 12, 24, and 60 months aft er their baseline visit. At each research visit fasting blood samples were obtained from metabolically stable participants (defi ned as no episode of diabetic ketoacidosis during the previous month), physical measurements were collected, and questionnaires were administered. The study was reviewed and approved by the local Institutional Review Board(s) that had jurisdiction over the local study population and all participants provided informed consent and/or assent.
Measurements
Study visits occurred aft er an 8 h overnight fast. Participants did not take diabetes medicines the morning of the visit, and long-acting insulin was administered the evening before the visit and then discontinued. For youths aged ≥ 3 years, a brief physical examination was conducted including measurement of weight and height using standardized procedures and used to calculate body mass index [BMI (kg/m
2 )]. Age-and sex-specifi c BMI z -scores were calculated using growth charts with a SAS program available from the Centers for Disease Control and Prevention (13) . Waist circumference was measured using NHANES III protocol (14) . Race and ethnicity were self-reported using 2000 US Census questions (15) and classifi ed as Hispanic, non-Hispanic white (NHW), non-Hispanic black (NHB), American Indian (AI), and Asian/Pacifi c Islander (API). For these analyses, race/ ethnicity was categorized as NHW and other than non-Hispanic white, including all other racial/ethnic groups.
Fasting blood samples were used to analyze diabetes autoantibodies (DA), hemoglobin A1C (A1C) and fasting C-peptide (FCP). Assays were performed at the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, the Central Laboratory for SEARCH. Glutamic acid decarboxylase-65 (GADA) and insulinoma-associated-2 (IA-2A) autoantibodies were analyzed using a standardized protocol and a common serum calibrator developed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored standardization group (16) . The cutoff values for positivity were 33 NIDDKU/mL for GAD65 and 5 NIDDKU/mL for IA2 (16) . A1C (%) was measured in whole blood with an automated nonporous ion-exchange high-performance liquid chromatography system (model G-7; Tosoh Bioscience, Montgomeryville, PA, USA). Levels of FCP were determined by a two-site immunoenzymetric assay (Tosoh AIA, Tosoh Bioscience Inc., San Francisco, CA, USA). The assay sensitivity was 0.05 ng/mL.
Presence of diabetes in the biological mother and the age of diagnosis were obtained by self-report from the participant or their parent. Information on maternal diabetes type was not collected. Study participants whose mothers had diabetes were classifi ed based on the timing of the mother ' s diagnosis relative to the subject ' s birth. Classifi cation of exposure to diabetes in utero among SEARCH study has been reported previously (6) . Subjects whose mothers had diabetes before their birth were classifi ed as " exposed to in utero diabetes " . Subjects whose mothers did not have diabetes or who were diagnosed aft er the birth of the index child were classifi ed as " unexposed " . Subjects who had missing data on mother ' s diabetes status or timing of diagnosis were excluded from this analysis.
Study participants
Inclusion criteria for this report include all youth < 20 years from SEARCH recruitment sites from 2002 through to 2005 with newly diagnosed type 1 diabetes plus DA positivity at the baseline visit (either GADA or IA-2A) or type 2 diabetes with the absence of DA positivity at the baseline visit. Exclusion criteria include: youth whose diabetes type or DA status were missing, youth with type 1 diabetes who were DA negative and youth with type 2 diabetes who were DA positive (n = 295). Subjects with incomplete or missing questionnaire data to determine in utero diabetes exposure were also excluded (n = 198). A total of 941 youth with type 1 and 138 youth with type 2 met these requirements, for a total of 1079 participants.
Data analysis
Comparisons of baseline participant characteristics, by in utero exposure to diabetes, were performed using t-tests for continuous variables, and χ 2 tests or Fisher ' s exact test for categorical variables, stratifi ed by diabetes type. To explore diff erences in the short-term rate of change in FCP levels by exposure to maternal diabetes in utero, mixed eff ects linear models accounting for within subject correlation were used to model the rate of change in FCP levels, stratifi ed by diabetes type, and adjusted for sex, race/ethnicity (nonHispanic white vs. other), age at diagnosis, clinic, parental education ( < high school vs. ≥ high school), total household income ( < $ 25,000 vs. ≥ $ 25,000/year), BMI z-score, and A1C. The models are longitudinal based on duration of disease and adjusted for the correlation between repeated measures in the same subject, allowing for a random slope and intercept. All continuous variables were evaluated for normality; due to a skewed distribution of FCP levels, values were log-transformed for these analyses. Predicted FCP rate of change was expressed as percent change in FCP level per month and 95% confidence interval. An interaction term between duration of disease and exposure to maternal diabetes in utero was the main covariate of interest. To test if the eff ect of maternal diabetes exposure on change in FCP was modifi ed by diabetes type, a supplemental model was created that combined youth with type 1 and type 2 diabetes and tested a 3-way interaction between diabetes type, exposure to maternal diabetes in utero, and duration of disease to determine if the eff ect of exposure on change in log-transformed FCP over time was diff erent for youth with type 1 and type 2 diabetes. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA). Results were considered signifi cant if p < 0.05.
Results
Characteristics of study participants with type 2 (n = 138) and type 1 diabetes (n = 941), according to exposure to maternal diabetes in utero , appear in Table 1 . Exposure to maternal diabetes in utero occurred in 14.5% (n = 20) of youth with DA negative, type 2 diabetes and 1.8% (n = 17) of youth with DA positive type 1 diabetes. As reported previously (6) , youth with type 2 diabetes who were exposed to maternal diabetes in utero had a younger age (years) at diagnosis (11.3 ± 2.1 vs. 13.7 ± 2.3, p < 0.0001) and, therefore, were younger (years) at the baseline visit (12.5 ± 2.1 vs. 15.0 ± 2.3, p < 0.0001) than those not exposed. However, for both youth with type 2 and type 1 diabetes, other participant characteristics, including sex, race/ethnicity, parental level of education, total household income, paternal history of diabetes status, were not significantly different for those unexposed and exposed to maternal diabetes in utero. In addition, participant characteristics at the baseline visit including FCP levels, BMI z -score, and A1C, were not significantly different by exposure status for youth with type 2 or type 1 diabetes. Table 2 shows the predicted FCP levels of SEARCH participants with type 2 and type 1 diabetes according to in utero exposure status from the type-stratified longitudinal linear mixed model adjusted for age at diagnosis, sex, race/ethnicity, clinic, parental education, household income, BMI z -score, and A1C. No significant differences were detected in predicted FCP levels by in utero exposure to maternal diabetes among either youth with type 2 or type 1 diabetes. For youth with type 2 diabetes, model predicted FCP levels at 6 months post diagnosis were 3.53 ng/mL (95%CI: 3.04, 4.10) vs. 2.94 ng/mL (95%CI: 2.30, 3.74) for the unexposed and exposed, respectively. At 30 months post diagnosis, youth with type 2 diabetes had a model predicted FCP level of 3.18 ng/mL (95%CI: 2.74, 3.70) among the unexposed and 2.65 ng/mL (95%CI: 2.08, Table 1 Characteristics of youth with diabetes in SEARCH study at baseline visit, according to exposure to diabetes in utero: mean ± SD or n (%).
Participants with type 2 diabetes
Participants with type 1 diabetes Figure 1 shows the estimated decline in FCP levels over time among youth with type 2 and type 1 diabetes by exposure to maternal diabetes in utero from the type-stratified longitudinal linear mixed effect models. The estimated monthly rate of change in FCP levels was -0.43% (95%CI: -0.17, -0.69) among youth with type 2 and -3.11% (95%CI: -3.00, -3.21) among youth with type 1 diabetes. The rate of change in β cell function was not significantly different by exposure to maternal diabetes in utero for youth with type 2 (p = 0.16) or type 1 diabetes (p = 0.90). Overall, exposure to diabetes in utero was associated with 17% lower FCP levels among youth with type 2 diabetes (95% CI: -34%, + 6%) and 15% higher FCP levels for youth with type 1 diabetes (95% CI: -14%, + 55%), although these differences were not statistically significant (p = 0.13 and p = 0.35, respectively). Finally, in the model combining youth with type 1 and type 2 diabetes, the effect of exposure to maternal diabetes in utero on β cell rate of change was not significantly modified by youth diabetes type (p = 0.41).
Discussion
This study found no evidence that exposure to maternal diabetes in utero is associated with the β cell function soon after diagnosis or the decline in β -cell function in the first few years following diagnosis among youth with type Adjusted for sex, race, age at diagnosis, clinic, parental education, household income, baseline body mass index z-score, and A1C. FCP, fasting C-peptide. Model adjusted for sex, race, age at diagnosis, clinic, parental education, household income, maternal exposure to diabetes, BMI z-score, and hemoglobin A1C.
1 or type 2 diabetes. Although in this sample of SEARCH cohort study participants, in utero exposure to maternal diabetes was associated with younger age at diagnosis with type 2 diabetes, confirming previous findings in the larger SEARCH study (6) , exposure to maternal diabetes was not a significant predictor of β cell function at baseline or short-term β cell decline in these youth. A limited number of studies have explored factors associated with β cell decline in youth with either type 2 or type 1 diabetes and, to our knowledge, none have specifically assessed the effect of exposure to diabetes in utero on β cell decline following diagnosis of diabetes. Both animal and human studies suggest an adverse influence of maternal diabetes on fetal β -cell function which may contribute to development of type 2 diabetes (17 -21) . In utero exposure to maternal diabetes in a streptozotocin (STZ)-induced rat model results in changes to the morphology, number and size of offspring islets, with impaired insulin secretion (17, 18) . At 15 weeks, isolated islets from rat offspring exposed to STZ-induced maternal diabetes showed low insulin secretion in response to a high (16 mM) glucose challenge, compared to control rats. Studies in humans are limited, but suggest that exposure to maternal hyperglycemia in utero results in impaired insulin secretion (19) , leading to impaired glucose tolerance later in life (20, 21) . Among Pima Indian adults the acute insulin response to infused glucose was 40% lower in individuals whose mothers had diabetes during pregnancy than in those whose mothers developed diabetes after the birth of the subject (20) .
Although small studies have suggested that youth with type 2 diabetes have some degree of β -cell dysfunction at diagnosis (22, 23) , there are no large prospective studies of the natural evolution and determinants of β -cell function in youth with type 2 diabetes. The situation is even more complex given the lack of a standardized definition of type 2 diabetes in youth. A study of 66 children with provider-defined type 2 diabetes at the Children ' s Hospital of Philadelphia (24) found that FCP levels at diagnosis were significantly lower in youth who presented in diabetic ketoacidosis (DKA) (1.08 ng/mL vs. 3.04 ng/mL when DKA was absent). Although the rate of decline in FCP levels was not assessed in this study, the authors hypothesized an initial slow decline in the first years following diagnosis, followed by a steeper decline with longer duration. In contrast, among youth with autoimmune diabetes, several clinical trial studies reported a 50% decline in the first year post-diagnosis (25 -28) . Our data in a selected sample of SEARCH cohort study participants are consistent with previous studies reporting a very slow progression of β -cell dysfunction in youth with antibody negative, type 2 diabetes (0.4% decline per month) and a steeper decline in those with antibody positive type 1 diabetes (3.1% per month) during the first few years following diabetes diagnosis.
We found that short-term decline in β cell function was not significantly associated with exposure to maternal diabetes in utero for youth with type 2 or type 1 diabetes. Our findings suggest that the onset and progression of disease among youth with type 1 diabetes is little, if any, affected by exposure to maternal diabetes during the intrauterine life (in fact overall FCP levels were insignificantly higher in exposed youth). However, among youth with type 2 diabetes, the decline in β cell function is likely to be more gradual compared to the decline among youth with type 1 diabetes (24) . Although we did not find a significant association between exposure to diabetes in utero and rate of change in FCP levels in the first few years post-diagnosis among youth with type 2 diabetes, this is a time when there is little β -cell loss, so our study findings cannot rule out an impact on longer-term decline of β cell decline. Therefore, longer follow-up of youth with type 2 diabetes is needed to conclusively address this issue.
Our study has several limitations including the use of FCP rather than stimulated C-peptide to assess baseline and change in β cell function over time. Stimulated C-peptide provides a direct measure of β cell function in response to a stimulus such as a mixed meal or glucagon challenge whereas FCP measures β -cell function in a basal state therefore entailing a greater degree of variability (29) . However, several studies have previously reported that FCP levels correlate well with those of stimulated C-peptide (30 -32) . Exposure was defined by self-report of maternal diabetes status and time of diagnosis. Self-report was provided by parents for younger subjects and by the subjects themselves for those who were older. It is possible that parents were more likely to accurately report the timing of maternal diagnosis than the subjects themselves therefore leading to some misclassification among older subjects. As such misclassification is unlikely to be differential by offspring β cell function at follow-up, it would result, if present, in a bias toward the null. An additional limitation is the small sample of youth exposed to diabetes in utero (20 exposed with type 2 diabetes, 17 exposed with type 1 diabetes), therefore, some of the non-significant associations, particularly among youth with type 2 diabetes, may have been the result of the small sample. A post-hoc power calculation suggests that a sample of 1000 exposed and 10,000 unexposed youth with type 1 diabetes would be needed to achieve 80% power for the observed difference to be statistically significant. For youth with type 2 diabetes, the power calculation estimated that 410 exposed and 2100 unexposed participants would be necessary to achieve 80% power for the observed difference to be statistically significant. Given the large number of exposed subjects needed to observe a significant difference, it is unlikely that this is a clinically meaningful exposure, especially in youth with type 1 diabetes. SEARCH is one of the largest studies of type 2 diabetes in youth conducted to date, including both assessment of both longitudinal change in FCP and in utero exposure to maternal diabetes. Our study has other important strengths including the use of a well characterized sample of youth with both type 1 and type 2 diabetes whose diabetes type was carefully defined based on both provider assessment and measurement of DA at baseline visit, and careful collection of exposure data.
This study suggests that exposure to maternal diabetes in utero is not significantly associated with the shortterm post-diagnosis progression of β -cell dysfunction in youth with type 1 or type 2 diabetes. Nevertheless, our results call for larger studies, as well as longer term follow up of youth with type 2 diabetes, to conclusively assess the long-term effects of in utero exposure on β -cell function in this population.
